BioSpace News Archive

Cigna and Banner Health have reached a long-term agreement that ensures Cigna customers will have access to quality care at Banner hospitals at predictable, affordable rates.

Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO, OTCQX: VREOF), the science-focused multi-state cannabis company with active operations in exclusively medical-only markets and licenses in 10 states and the commonwealth of Puerto Rico, today announced the Company will be relying on the general order of the British Columbia Securities Commission

Meeting to be held by webcast as a result of public health measures in response to the COVID-19 pandemic

Around 40% of Americans could not cover an unexpected $400 expense in 2018, which is less than one-third of the average health insurance deductible for an individual that year. Health care costs and deductibles have since continued to rise, along with the need for American consumers to have access to price information.

Patent covers first-of-its-kind solution that allows clinicians to perform procedures through ventilation mask without disrupting therapeutic pressure

Study examines if colchicine, a common gout medication, can reduce complications associated with COVID-19, slow disease progression, and save patient lives

Fiagon, a technology leader who develops and manufactures innovative surgical image guidance technologies, announced today a partnership with Smith+Nephew (NYSE: SNN, LSE: SN), a global medical technology business, to distribute its ENT surgical navigation portfolio in the Asia Pacific Asean region

Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with AbbVie’s pending acquisition of Allergan.

Today, the U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.